Both increased graft rejection and increased graft vs host disease (GVHD) remain obstacles to success for unrelated donor (URD) BMT for patients with SAA. Partial T cell depletion (PTCD) may decrease ...

MaaT Pharma to Present Four Abstracts at the 52nd EBMT Annual Meeting and to Highlight Clinigen-Hosted Industry Symposium on acute GvHD Management ...

Posttransplant cyclophosphamide–containing prophylaxis correlated with lower aGVHD risk than tacrolimus/methotrexate, and ATG/alemtuzumab use contributed to risk estimation. Clinical utility includes ...

Graft-versus-host disease (GVHD) is a life-threatening condition that can occur after an allogeneic stem cell transplant, which is a procedure that some blood cancer patients choose as it may offer ...

Learn coping strategies and tips to manage sexual problems from chronic GVHD.

Jak1/2 inhibitor ruxolitinib is a promising agent for treating steroid-refractory GvHD after allogeneic hematopoietic stem cell transplantation (SCT) to produce quick and durable responses. However, ...

(BPT) - For many people with cancer and other life-threatening diseases, stem cell transplants provide hope and can impact the course of the disease, but they also come with risks. One of those risks ...

There are now more drugs than ever to treat and prevent graft-versus-host disease in patients with blood cancer who receive a stem cell transplant. For many patients with blood cancers, an allogeneic ...

Hutchinson Center researchers have developed a new drug therapy that significantly reduces death from gastrointestinal graft-vs.-host disease in allogeneic stem-cell transplant patients. By adding a ...